Feiyan Mo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Feiyan Mo has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Ben Z. Stanger
Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
31 shared publications - Benjamin M. Kahn
Department of Medicine, Perelman School of Medicine, University of Pennsylvania (UPenn), Philadelphia, Pennsylvania
30 shared publications - Caius G. Radu
Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, USA
30 shared publications - Cynthia Clendenin
University of Pennsylvania Perelman School of Medicine, Abramson Cancer Center, Philadelphia, USA
30 shared publications - Il-Kyu Kim
Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
30 shared publications - James G. Christensen
Mirati Therapeutics, San Diego, California
30 shared publications
Latest Publications
- Open Access
Integrating activation-induced costimulation and cytokine signals enhance TCR-based cell therapies
TCR-based cell therapies offer broad targeting of tumor antigens with high sensitivity but often low durability due to insufficient costimulation (signal 2) and cytokine (signal 3) support. To address this, we developed a dual stimulatory receptor (DSR) consisting of the 4-1BBL ectodomain fused to the thrombopoietin receptor (cMPL) endodomain. DSR engages 4-1BB that is transiently upregulated upon TCR stimulation eliciting signal 2 and simultaneously activates cMPL-driven STAT3/5 phosphorylation providing signal 3. DSR increases the expansion of T cells, preserving their effector function and an effector-associated transcriptional profile upon repeated antigen stimulation. DSR arming significantly improves in vivo antitumor activity of T cells redirected to cancer through engineered TCRs or soluble T-cell engagers in diverse xenograft tumor models by enhancing T cell expansion and persistence post-infusion. These results demonstrate broad utility and establish DSR as a modular receptor for the effective and synchronized delivery of signals 2 and 3 to support TCR-based immunotherapies.
Open AccessIntegrating activation-induced costimulation and cytokine signals enhance TCR-based cell therapies
TCR-based cell therapies offer broad targeting of tumor antigens with high sensitivity but often low durability due to insufficient costimulation (signal 2) and cytokine (signal 3) support. To address this, we developed a dual stimulatory receptor (DSR) consisting of the 4-1BBL ectodomain fused to the thrombopoietin receptor (cMPL) endodomain. DSR engages 4-1BB that is transiently upregulated upon TCR stimulation eliciting signal 2 and simultaneously activates cMPL-driven STAT3/5 phosphorylation providing signal 3. DSR increases the expansion of T cells, preserving their effector function and an effector-associated transcriptional profile upon repeated antigen stimulation. DSR arming significantly improves in vivo antitumor activity of T cells redirected to cancer through engineered TCRs or soluble T-cell engagers in diverse xenograft tumor models by enhancing T cell expansion and persistence post-infusion. These results demonstrate broad utility and establish DSR as a modular receptor for the effective and synchronized delivery of signals 2 and 3 to support TCR-based immunotherapies.
- Open Access
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
MRTX1133 selectively inhibits KRASG12D and downstream MAPK signaling in vitro
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
MRTX1133 selectively inhibits KRASG12D and downstream MAPK signaling in vitro
- Open Access
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
MRTX1133 is selective for KRASG12D in immunocompetent implantation tumor models
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
MRTX1133 is selective for KRASG12D in immunocompetent implantation tumor models
- Open Access
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
MRTX1133 reduces metastatic burden in a tail vein model
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
MRTX1133 reduces metastatic burden in a tail vein model
- Open Access
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Materials from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
Supplementary Figures and Table with legend arranged in a single presentable package
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
Supplementary Figures and Table with legend arranged in a single presentable package
- Open Access
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
MRTX1133 exerts in vivo effects early in treatment
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
MRTX1133 exerts in vivo effects early in treatment
- Open Access
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
KRASG12D inhibition alters the tumor immune microenvironment
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
KRASG12D inhibition alters the tumor immune microenvironment
- Open Access
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
MRTX1133 elicits changes in the tumor stroma and vasculature
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
MRTX1133 elicits changes in the tumor stroma and vasculature
- Open Access
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
Effects of MRTX1133 in KPC/Y and subcutaneous models
- 10 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer
Effects of MRTX1133 in KPC/Y and subcutaneous models